| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4869939
Max Phase: Preclinical
Molecular Formula: C23H23N5O
Molecular Weight: 385.47
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: N#Cc1ccc2ncnc(NCCc3ccc(C(=O)N4CCCCC4)cc3)c2c1
Standard InChI: InChI=1S/C23H23N5O/c24-15-18-6-9-21-20(14-18)22(27-16-26-21)25-11-10-17-4-7-19(8-5-17)23(29)28-12-2-1-3-13-28/h4-9,14,16H,1-3,10-13H2,(H,25,26,27)
Standard InChI Key: QBKZFZYAFZYTFY-UHFFFAOYSA-N
Associated Targets(Human)
Cyclin-dependent kinase 1 3927 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 385.47 | Molecular Weight (Monoisotopic): 385.1903 | AlogP: 3.78 | #Rotatable Bonds: 5 |
| Polar Surface Area: 81.91 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 4.62 | CX LogP: 3.51 | CX LogD: 3.51 |
| Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.72 | Np Likeness Score: -1.53 |
References
| 1. (2019) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer, |
Source
Source(1):